Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ:RYTM
RESEARCH TOOLSreports
RYTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$35.17 - $68.58
Previous CloseN/A
Volume91.33K
Average Volume (3M)461.03K
Market Cap
$3.48B
Enterprise Value$3.16B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Feb 26, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.34
Shares Outstanding61,457,070
10 Day Avg. Volume380,580
30 Day Avg. Volume461,033
Standard Deviation0.35
R-Squared0.10
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)30.96
Price to Cash Flow (P/CF)-34.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit46.44
Enterprise Value/Ebitda-13.29
Forecast
1Y Price Target
$70.50Price Target Upside21.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Rhythm Pharmaceuticals News
See All RYTM News
---
Bulls Say, Bears Say
Bulls Say
Drug Development And InnovationRYTM is developing drugs for rare genetic obesity and already commercial with Imcivree for BBS annualizing at $100M+ revenue and ramping towards $500M+ peak.
Phase 3 Trial OutcomesRYTM is one of the top picks with high conviction in the Phase 3 data for setmelanotide for hypothalamic obesity.
Sales PerformanceRhythm Pharmaceutical pre-announced 4Q24 and FY24 Imcivree revenues ahead of expectations.
Bears Say
Cost ChallengesThere are structural hurdles most notably Imcivree’s high cost.
Intellectual Property And Revenue LimitationsExpectations are already high and there's not enough time to fully capitalize and get to peak revenue if intellectual property expires in 2032.
Long-term Medication AdherenceMost people do not stay on anti-obesity medication long term and regain most of the weight.
---
Ownership Overview
0.57% Insiders
26.31% Mutual Funds
0.31% Other Institutional Investors
60.92% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $35.17 and its highest was $68.58 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $3.48B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Feb 26, 2025 which is in 6 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Nov 05, 2024. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.805 by $0.075.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.69.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 61,457,070 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.805. Following the earnings report the stock price went up 11.378%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
---
Rhythm Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.50 (21.55% Upside)
$70.50 (21.55% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.90%
12-Months-Change
Fundamentals
Return on Equity
-248.12%
Trailing 12-Months
Asset Growth
2.65%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.
---
RYTM Company Deck
---
RYTM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with steady revenue growth, significant international expansion, and promising clinical data, particularly in hypothalamic obesity. However, challenges remain in managing high expenses and patient retention.Read More>---
RYTM Stock 12 Month Forecast
Average Price Target
$70.50
▲(21.55% Upside)
Technical Analysis
Seres Therapeutics
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Immunovant
―
Arcutis Biotherapeutics
―
Best Analysts Covering RYTM
1 Year
1 Year Success Rate
15/16 ratings generated profit
1 Year Average Return
+58.91%
reiterated a buy rating 3 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 93.75% of your transactions generating a profit, with an average return of +58.91% per trade.
---